Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. 1988

J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
Department of Gastroenterology, St Radboud Hosptial Nijmegen, The Netherlands.

Single intravenous doses of 10, 20, 40, and 80 mg and repeated once daily intravenous doses of 10 and 20 mg omeprazole induced a powerful and long lasting inhibition of pentagastrin stimulated gastric acid secretion (PAO) in healthy male volunteers. Single intravenous doses of 10, 20, 40, and 80 mg omeprazole inhibited PAO by 30% (p less than 0.01), 45% (p less than 0.01), 61% (p less than 0.01), and 80% (p less than 0.01), respectively when measured 1.5 h after dose, and by 20% (NS), 27% (NS), 36% (p less than 0.01) and 59% (p less than 0.01), respectively when measured 24 h after dose. Six days after repeated once daily intravenous doses of 10 and 20 mg omeprazole, PAO was inhibited by 63% (p less than 0.01) and 82% (p less than 0.01), respectively when measured 1.5 h after dose, and by 32% (p less than 0.01) and 43% (p less than 0.01), respectively when measured 24 h after dose. The inhibition of PAO by 10 mg administered intravenously as a single bolus injection was comparable with the inhibition by 20 mg as a single oral dose. Repeated once daily administration of 10 mg intravenously and 20 mg orally also resulted in comparable reductions in PAO. The reduction in PAO after repeated once daily oral administration of 20 mg was comparable with the effect of a single intravenous dose of 40 mg. Terminal half lives were short, but significantly (p less than 0.05) prolonged after a single intravenous injection of 80 mg. Repeated once daily intravenous administration of 10 and 20 mg did not result in prolongation of terminal half lives. It is concluded that intravenous administration of omeprazole causes a potent and long acting inhibition of pentagastrin stimulated gastric acid secretion in man. Its potency is augmented after repeated once daily administration.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D010418 Pentagastrin A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. Acignost,Gastrin Pentapeptide,Peptavlon,Pentapeptide, Gastrin
D005744 Gastric Acid Hydrochloric acid present in GASTRIC JUICE. Hydrochloric Acid, Gastric,Acids, Gastric,Acids, Gastric Hydrochloric,Gastric Acids,Gastric Hydrochloric Acid,Gastric Hydrochloric Acids,Hydrochloric Acids, Gastric
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
April 1983, Gut,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
September 1984, Digestive diseases and sciences,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
July 1984, Gut,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
April 1983, Gastroenterologie clinique et biologique,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
February 1980, Digestive diseases and sciences,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
April 1987, Alimentary pharmacology & therapeutics,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
January 1975, Acta chirurgica Scandinavica,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
October 1985, Scandinavian journal of gastroenterology,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
January 1977, Scandinavian journal of gastroenterology,
J B Jansen, and P Lundborg, and L C Baak, and J Greve, and M Ohman, and C Stöver, and K Röhss, and C B Lamers
December 1968, Gut,
Copied contents to your clipboard!